![The World Congress on Controversies in Obstetrics, Gynecology and Infertility (COGI). Click here to learn more.]({"type":"image" , "src" : "/sda/112382/JournalAd-COGI2024-Leaderboard.jpg"})
References
- AlHilli MM, Long HJ, Podratz KC, Bakkum-Gamez JN. 2012. Aromatase inhibitors in the treatment of recurrent ovarian granulosa cell tumors: brief report and review of the literature. Journal of Obstetrics and Gynaecology Research 38:340–344.
- Bridgewater JA, Rustin GJS. 1999. Management of non-epithelial ovarian tumors. Oncology 57:89–98.
- Brown J, Shvartsman HS, Deavers MT et al. 2005. The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors. Gynecologic Oncology 97:489–496
- Buzdar AU. 2002. Anastrozole (Arimidex) in clinical practice versus the old “gold standard”, tamoxifen. Expert Review of Anticancer Therapy 2:623–629.
- Freeman SA, Modesitt SC. 2006. Anastrozole therapy in recurrent ovarian adult granulosa cell tumors: a report of two cases. Gynecologic Oncology 103:755–758.
- Homesley HD, Bundy BN, Hurteau JA, Roth LM. 1999. Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: a Gynecologic Oncology Group study. Gynecologic Oncology 72:131–137.
- Korach J, Perri T, Beiner M et al. 2009. Promising effect of aromatase inhibitors on recurrent granulosa cell tumors. International Journal of Gynecologic Cancer 19:830–833.
- Pectasides D, Pectasides E, Psyrri A. 2008. Granulosa cell tumor of the ovary. Cancer Treatment Reviews 34:1–12.